Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
We review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti-VEGF antibodies, and also evaluating their outcomes. Intraocular injections of anti-VEGF drug are considered to be an effective treatment for macular edema after retin...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2012/852183 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562097047732224 |
|---|---|
| author | Kenichi Kimoto Toshiaki Kubota |
| author_facet | Kenichi Kimoto Toshiaki Kubota |
| author_sort | Kenichi Kimoto |
| collection | DOAJ |
| description | We review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti-VEGF antibodies, and also evaluating their outcomes. Intraocular injections of anti-VEGF drug are considered to be an effective treatment for macular edema after retinal vein occlusion, however, recurrent/persistent edema is common. The recent reports may lead to a shift in treatment paradigm for DME, from laser photocoagulation, to newer approaches using anti-VEGF drugs. There have been several well-publicized prospective, randomized studies that demonstrated the efficacy of intravitreal injection of anti-VEGF drugs for patients with AMD. Adjuvant bevacizumab for neovascular glaucoma may prevent further PAS formation, and it is likely to open up a therapeutic window for a panretinal photocoagulation and trabeculectomy. Intravitreal injection of bevacizumab (IVB) results in a substantial decrease in bleeding from the retinal vessels or new vessels during a standard vitrectomy. IVB has also been reported to be effective for inducing the regression of new vessels in proliferative diabetic retinopathy. The use of bevacizumab in stage 4 or 5 retinopahty of permaturity (ROP) is to reduce the plus sign to help reduce hemorrhage during the subsequent vitrectomy. Some authors reported cases of resolution of stage 4 A ROP after bevacizumab injection. |
| format | Article |
| id | doaj-art-11d8212017ce46ef9bb68f8d538dec5b |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-11d8212017ce46ef9bb68f8d538dec5b2025-02-03T01:23:22ZengWileyJournal of Ophthalmology2090-004X2090-00582012-01-01201210.1155/2012/852183852183Anti-VEGF Agents for Ocular Angiogenesis and Vascular PermeabilityKenichi Kimoto0Toshiaki Kubota1Department of Ophthalmology, Oita University, Faculty of Medicine, Hasama-machi, Yufu-shi, Oita 879-5593, JapanDepartment of Ophthalmology, Oita University, Faculty of Medicine, Hasama-machi, Yufu-shi, Oita 879-5593, JapanWe review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti-VEGF antibodies, and also evaluating their outcomes. Intraocular injections of anti-VEGF drug are considered to be an effective treatment for macular edema after retinal vein occlusion, however, recurrent/persistent edema is common. The recent reports may lead to a shift in treatment paradigm for DME, from laser photocoagulation, to newer approaches using anti-VEGF drugs. There have been several well-publicized prospective, randomized studies that demonstrated the efficacy of intravitreal injection of anti-VEGF drugs for patients with AMD. Adjuvant bevacizumab for neovascular glaucoma may prevent further PAS formation, and it is likely to open up a therapeutic window for a panretinal photocoagulation and trabeculectomy. Intravitreal injection of bevacizumab (IVB) results in a substantial decrease in bleeding from the retinal vessels or new vessels during a standard vitrectomy. IVB has also been reported to be effective for inducing the regression of new vessels in proliferative diabetic retinopathy. The use of bevacizumab in stage 4 or 5 retinopahty of permaturity (ROP) is to reduce the plus sign to help reduce hemorrhage during the subsequent vitrectomy. Some authors reported cases of resolution of stage 4 A ROP after bevacizumab injection.http://dx.doi.org/10.1155/2012/852183 |
| spellingShingle | Kenichi Kimoto Toshiaki Kubota Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability Journal of Ophthalmology |
| title | Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability |
| title_full | Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability |
| title_fullStr | Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability |
| title_full_unstemmed | Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability |
| title_short | Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability |
| title_sort | anti vegf agents for ocular angiogenesis and vascular permeability |
| url | http://dx.doi.org/10.1155/2012/852183 |
| work_keys_str_mv | AT kenichikimoto antivegfagentsforocularangiogenesisandvascularpermeability AT toshiakikubota antivegfagentsforocularangiogenesisandvascularpermeability |